Sandoz’s Lek Invests in Final Dosage Form Biosimilar Capabilities
Lek, a Sandoz company, the generics arm of Novartis, has invested EUR 10 million ($10.8 million) at its site in MengeÅ¡, Slovenia, to add new laboratories for the development of final dosage forms for biosimilars, quality control, and biopharmaceuticals technical development. With the investment, final dosage forms for biosimilars will now be developed at the site adding to existing capabilities for active pharmaceutical ingredient development (API).
Lek functions as a global development center for technologically demanding products and technologies, a global manufacturing center for APIs and medicine, a competence center for the development of vertically integrated products, a Sandoz competence center in the field of development and manufacturing of biosimilar products, and a supply center for the markets of Central and Eastern Europe, South East Europe, and the Commonwealth of Independent States (CIS), and is responsible for sales on the Slovenian market.
In total, Novartis has invested more than EUR 64 million in development as well as production at MengeÅ¡.